Preoperative Chemoradiation for Patients With Pancreatic Cancer: Toxicity of Endobiliary Stents
- 14 February 2000
- journal article
- gastrointestinal oncology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (4), 860
- https://doi.org/10.1200/jco.2000.18.4.860
Abstract
PURPOSE: A recent multicenter study of preoperative chemoradiation and pancreaticoduodenectomy for localized pancreatic adenocarcinoma suggested that biliary stent–related complications are frequent and severe and may prevent the delivery of all components of multimodality therapy in many patients. The present study was designed to evaluate the rates of hepatic toxicity and biliary stent–related complications and to evaluate the impact of this morbidity on the delivery of preoperative chemoradiation for pancreatic cancer at a tertiary care cancer center. PATIENTS AND METHODS: Preoperative chemoradiation was used in 154 patients with resectable pancreatic adenocarcinoma (142 patients, 92%) or other periampullary tumors (12 patients, 8%). Patients were treated with preoperative fluorouracil (115 patients), paclitaxel (37 patients), or gemcitabine (two patients) plus concurrent rapid-fractionation (30 Gy; 123 patients) or standard-fractionation (50.4 Gy; 31 patients) radiation therapy. The incidences of hepatic toxicity and biliary stent–related complications were evaluated during chemoradiation and the immediate 3- to 4-week postchemoradiation preoperative period. RESULTS: Nonoperative biliary decompression was performed in 101 (66%) of 154 patients (endobiliary stent placement in 77 patients and percutaneous transhepatic catheter placement in 24 patients). Stent-related complications (occlusion or migration) occurred in 15 patients. Inpatient hospitalization for antibiotics and stent exchange was necessary in seven of 15 patients (median hospital stay, 3 days). No patient experienced uncontrolled biliary sepsis, hepatic abscess, or stent-related death. CONCLUSION: Preoperative chemoradiation for pancreatic cancer is associated with low rates of hepatic toxicity and biliary stent–related complications. The need for biliary decompression is not a clinically significant concern in the delivery of preoperative therapy to patients with localized pancreatic cancer.Keywords
This publication has 17 references indexed in Scilit:
- Adjuvant Radiotherapy and 5-Fluorouracil After Curative Resection of Cancer of the Pancreas and Periampullary RegionAnnals of Surgery, 1999
- Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.Journal of Clinical Oncology, 1998
- Molecular metastases in stage I pancreatic cancer: Improved survival with adjuvant chemoradiationSurgery, 1998
- Periampullary AdenocarcinomaAnnals of Surgery, 1998
- Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study.Journal of Clinical Oncology, 1998
- Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: Postoperative Adjuvant Chemoradiation Improves SurvivalAnnals of Surgery, 1997
- Long-Term Survival After Curative Resection for Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 1996
- Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic headThe American Journal of Surgery, 1996
- Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the PancreasArchives of Surgery, 1992
- Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancerCancer, 1987